share_log

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target

RBC Capital重申Viridian Therapeutics的买入评级,维持44美元目标价。
Benzinga ·  12/06 00:05  · 评级/大行评级

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $44 price target.

RBC资本分析师Gregory Renza重申对Viridian Therapeutics(纳斯达克:VRDN)的跑赢大盘评级,并维持44美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发